News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Market source Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Celcuity (NASDAQ:CELC) recently reported its quarterly earnings, missing analyst estimates with a loss of $1.44 per share against a consensus of $1.16, and revenue of $0.09 million, significantly below the $4.42 million forecast. Despite the financial miss, the company highlighted the FDA approval of …
Celcuity Inc. has received a "Buy" rating following the FDA approval of its cancer drug REVTORPYK/gedatolisib and its quick inclusion in NCCN Category 1 guidelines, which is expected to aid adoption. Despite high upfront commercial investments and a significant valuation, the company's strong cash …
Stifel lowered its price target for Celcuity Inc. (NASDAQ:CELC) to $150 from $175, while maintaining a Buy rating, citing refined market model inputs for Revtorpyk and higher future administrative expenses. Despite the stock's strong performance, InvestingPro analysis suggests it might be overvalued, and analysts …
Analysts have adjusted Celcuity Inc.'s average 12-month price target from $163.55 to $160.64, with individual forecasts ranging from $140 to $178 per share. This new target suggests an 85% potential upside from the Aug. 13 closing price. The consensus rating for Celcuity Inc. remains …
Needham has reduced its price target for Celcuity Inc (NASDAQ:CELC) shares to $140 from $157, while maintaining a Buy rating. This adjustment follows the approval and upcoming launch of Revtorpyk, with Needham updating its revenue models to an incidence-based approach and incorporating new pricing …
Celcuity Inc. announced its Q2 2026 financial results, highlighted by the FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- PIK3CA Wild-Type breast cancer and its inclusion in NCCN guidelines. The company plans a commercial launch for REVTORPYK in late Q3 2026 and intends to submit …
Celcuity (CELC) has received FDA approval for REVTORPYK for certain metastatic breast cancer patients and its inclusion in NCCN guidelines. Despite this positive news, the stock has experienced a significant pullback, falling 22% over 30 days and 37.1% over 90 days. Analysts currently value …
Key Points Interested in Celcuity, Inc.? Here are five stocks we like better. REVTORPYK launch remains on track: Celcuity expects commercial shipments of its FDA-approved gedatolisib therapy for certain advanced breast cancer patients to begin in late Q3 2026. The treatment has a $30,000 …
Celcuity Inc. (CELC) received FDA approval for REVTORPYK for HR-positive, HER2-negative advanced breast cancer, supported by strong trial data and NCCN guideline inclusion. Despite a Q2 net loss of $78.9M, the company has a robust cash position due to a $575M convertible note, setting …
Celcuity Inc. reported an adjusted loss of $1.07 per share for the second quarter of 2026, surpassing analyst estimates. The company's shares rose 1% after the announcement, driven by the recent FDA approval of its breast cancer treatment, REVTORPYK. Celcuity expects to begin shipments …
* Celcuity press release [https://seekingalpha.com/pr/20619145-celcuity-inc-reports-release-of-second-quarter-2026-financial-results-and-provides-corporate] (CELC [https://seekingalpha.com/symbol/CELC]): Q2 GAAP EPS of -$1.44 misses by $0.28. * Total operating expenses were $66.1 million for the second quarter of 2026, compared to $44.0 million for the prior year period. Research and development (“R&D”) expenses were $31.1 …
Celcuity Inc. (CELC) reported a Q2 adjusted loss of $1.07 per share, which was better than the FactSet estimate of $-1.12 per share. The article, published on August 13, 2026, also noted that Celcuity's Q2 adjusted loss widened. This news follows several recent developments …
A near-term rebound contrasts with deeper medium-term losses before the oncology biotech reports.
Celcuity, Inc. (NASDAQ:CELC) has received an average "Moderate Buy" rating from eleven brokerages, with ten assigning a buy rating and one a sell rating. The average 12-month price target is $155.18, significantly higher than its current price of $92.08. The company recently reported quarterly …
An analysis of Celcuity Inc. (NASDAQ: CELC) indicates strong near-term sentiment but elevated downside risk. AI-generated trading strategies are provided for position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The article highlights the importance of institutional trading strategies for optimizing …
This page provides current news and analysis for Celcuity Inc (CELC), including its stock performance and market data. It lists recent stock movements for other pharmaceutical companies like Bristol-Myers Squibb Co (BMY), Novo Nordisk A/S (NVO), and Merck & Co Inc (MRK). The content …
Pomerantz LLP is investigating Celcuity Inc. for potential securities fraud. This follows a 17.6% stock drop on July 15, 2026, after Celcuity announced delays in the commercial launch of its FDA-approved breast cancer therapy, Revtorpyk. The investigation aims to determine if unlawful business practices …
This page provides a comprehensive overview of Celcuity Inc. (CELC) stock, including its real-time price, historical data, and financial performance. It highlights the company's focus on developing targeted therapies for solid tumors and its lead drug candidate, Gedatolisib. The page also includes analyst insights, …
Celcuity Inc. announced it will release its second quarter 2026 financial results after the market closes on Thursday, August 13, 2026. Management will host a webcast/teleconference on the same day at 4:30 p.m. Eastern Daylight Time to discuss the results and provide a corporate …
This article analyzes Celcuity Inc.'s path to profitability, focusing on analyst expectations for its breakeven point. It discusses the company's current losses and projected future performance, highlighting key financial metrics and growth forecasts. The article also provides insight into the factors influencing Celcuity's profitability …
Bragar Eagel & Squire, P.C., a stockholder rights law firm, is investigating potential claims against Celcuity Inc. (NASDAQ:CELC) following a significant drop in its stock price. The investigation stems from Celcuity's announcement of a delayed commercial launch for its breast cancer therapy, Revtorpyk, which …
Kirby McInerney LLP is investigating potential securities law violations by Celcuity Inc. (NASDAQ: CELC) and its senior management. This investigation follows a July 13, 2026, announcement by Celcuity regarding FDA approval for its breast cancer therapy, Revocirib, which included a delayed commercial launch timeline …
Bronstein, Gewirtz & Grossman, LLC is investigating Celcuity Inc. (NASDAQ:CELC) following a significant drop in its stock price. This decline occurred after Celcuity announced U.S. FDA approval for its breast cancer therapy Revtorpyk, but with a commercial launch timeline in late Q3 2026, which …
Schall, Brown & Schwartz LLP (SBS) has initiated an investigation into Celcuity Inc. (NASDAQ: CELC) on behalf of investors, following a significant drop in share price. The investigation concerns potential violations of securities laws, specifically focusing on whether Celcuity made false or misleading statements …
Celcuity recently received FDA approval and NCCN Category 1 preferred guideline status for its drug REVTORPYK (gedatolisib), specifically for HR+/HER2- breast cancer. This approval is significant as REVTORPYK is the only FDA-approved therapy targeting all class I PI3K isoforms and both mTORC1 and mTORC2 …
Search by ticker symbol or company name and select a result to open its chart.